SNPX vs. DRUG, GTBP, CPHI, SONN, SNGX, PXMD, KA, SEEL, PTPI, and ALZN
Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Bright Minds Biosciences (DRUG), GT Biopharma (GTBP), China Pharma (CPHI), Sonnet BioTherapeutics (SONN), Soligenix (SNGX), PaxMedica (PXMD), Kineta (KA), Seelos Therapeutics (SEEL), Petros Pharmaceuticals (PTPI), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical preparations" industry.
Bright Minds Biosciences (NASDAQ:DRUG) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.
Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.
40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 4.3% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Synaptogenix received 1 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
Bright Minds Biosciences' return on equity of -22.50% beat Synaptogenix's return on equity.
In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Bright Minds Biosciences'average media sentiment score.
Bright Minds Biosciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
Summary
Bright Minds Biosciences beats Synaptogenix on 5 of the 9 factors compared between the two stocks.
Get Synaptogenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synaptogenix Competitors List
Related Companies and Tools
